Sigma Delta Sigma Sigma Sigma -186 Sigma Sigma Sigma
Dissertationsschrift
Seiten
2009
GRIN Verlag
978-3-640-48449-2 (ISBN)
GRIN Verlag
978-3-640-48449-2 (ISBN)
- Titel ist leider vergriffen;
keine Neuauflage - Artikel merken
Doctoral Thesis / Dissertation from the year 2009 in the subject Medicine - Neoplasms, Oncology, National & Kapodistrian University of Athens ( Delta Sigma Sigma - ' Sigma Sigma), language: Modern Greek, abstract: Purpose: To prospectively evaluate the predictive value of various bone formation and resorption makers in patients with bone metastases from prostate cancer after palliative therapies with 186Rhenium-l,l-hydroxyethylidene diphosphonate (186Re-HEDP).
Methods: Thirty six males with prostate cancer, suffering from painful osseous metastases and treated with 186Rhenium-HEDP, were studied. None had received therapies that interfere with bone metabolism before 186Rhenium-HEDP therapy and throughout the follow-up period. For each patient, pre-therapy and post-therapy serum levels of osteocalcin (OC), bone alkaline phosphatase (BALP), amino-terminal (PINP) and carboxy-terminal (PICP) propeptides of type I collagen, amino-terminal (NTx) and carboxy-terminal (CTx) telopeptides of type I collagen and their combinations were compared to the level and duration of pain response to radionuclide therapies.
Results: Pain response was correlated only with pre-treatment values of x/PINP, PICP/PINP and NTx/CTx ratios and post-treatment decrease of baseline NTx and PICP values (P=0.0025-0.035). According to multivariate and ROC analyses, the best marker-derived predictors of better and longer duration of response to 186Rhenium-HEDP therapies proved post-therapy drop of NTx 20% (RR=3.44, P=0.0005) and pre-therapy NTx/PINP 1.2 (RR=3.04, P=0.036)
Conclusions: NTx, a potent collagenous marker of bone resorption, along with the novel NTx/PINP ratio provide useful cut-off values for identifying a group of patients suffering from painful osseous metastases from HRPC, who will not respond to palliative treatments with 186Rhenium-HEDP. This information could prevent an inefficient and expensive radionuclide therapy. Also, in the cohort of patients who will eventually undergo such treatments, the middle-term post-therapy changes of NTx offer valuable predictive information regarding long-term palliative response.
Methods: Thirty six males with prostate cancer, suffering from painful osseous metastases and treated with 186Rhenium-HEDP, were studied. None had received therapies that interfere with bone metabolism before 186Rhenium-HEDP therapy and throughout the follow-up period. For each patient, pre-therapy and post-therapy serum levels of osteocalcin (OC), bone alkaline phosphatase (BALP), amino-terminal (PINP) and carboxy-terminal (PICP) propeptides of type I collagen, amino-terminal (NTx) and carboxy-terminal (CTx) telopeptides of type I collagen and their combinations were compared to the level and duration of pain response to radionuclide therapies.
Results: Pain response was correlated only with pre-treatment values of x/PINP, PICP/PINP and NTx/CTx ratios and post-treatment decrease of baseline NTx and PICP values (P=0.0025-0.035). According to multivariate and ROC analyses, the best marker-derived predictors of better and longer duration of response to 186Rhenium-HEDP therapies proved post-therapy drop of NTx 20% (RR=3.44, P=0.0005) and pre-therapy NTx/PINP 1.2 (RR=3.04, P=0.036)
Conclusions: NTx, a potent collagenous marker of bone resorption, along with the novel NTx/PINP ratio provide useful cut-off values for identifying a group of patients suffering from painful osseous metastases from HRPC, who will not respond to palliative treatments with 186Rhenium-HEDP. This information could prevent an inefficient and expensive radionuclide therapy. Also, in the cohort of patients who will eventually undergo such treatments, the middle-term post-therapy changes of NTx offer valuable predictive information regarding long-term palliative response.
| Erscheint lt. Verlag | 9.12.2009 |
|---|---|
| Zusatzinfo | 1 Farbabb. |
| Sprache | Greek, Modern (1453-) |
| Maße | 148 x 210 mm |
| Themenwelt | Sachbuch/Ratgeber ► Beruf / Finanzen / Recht / Wirtschaft ► Erben / Vererben |
| Sachbuch/Ratgeber ► Beruf / Finanzen / Recht / Wirtschaft ► Recht / Sonstiges | |
| Medizin / Pharmazie ► Medizinische Fachgebiete | |
| ISBN-10 | 3-640-48449-5 / 3640484495 |
| ISBN-13 | 978-3-640-48449-2 / 9783640484492 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Textbausteine, Mustertestamente, Checklisten
Buch | Softcover (2025)
Verbraucher-Zentrale NRW (Verlag)
CHF 30,80
Handbuch für den Trauerfall
Buch | Softcover (2024)
Verbraucher-Zentrale NRW (Verlag)
CHF 25,20
